A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs OligoG (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors AlgiPharma
- 22 Mar 2017 This trial was completed in Germany (end date:2016-12-16), according to the European Clinical Trials Database record.
- 26 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.
- 26 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Feb 2017.